The Clinical Problem

Chronic pancreatic disease creates a documentation gap that undermines evidence-based care. Here is the clinical case for why longitudinal patient-generated data matters.

Epidemiological Context

These conditions overlap significantly. A patient with chronic pancreatitis commonly develops EPI and subsequently type 3c diabetes — each requiring distinct management approaches that interact with one another in ways that standard chronic disease frameworks do not address.

The Documentation Gap

Chronic pancreatic disease is characterized by high intra-patient variability. Pain severity, stool characteristics, fat tolerance, and glucose dynamics can shift dramatically over days — and shift in response to identifiable variables including diet composition, enzyme dosing, and stress.

Despite this variability, clinical data collection is episodic:

PERT Dosing as a Specific Problem

Pancreatic enzyme replacement therapy (PERT) dosing is notoriously difficult to optimize. Clinical guidelines recommend 500–2,500 lipase units per gram of dietary fat, titrated to symptom response. In practice:

• Patients cannot accurately recall fat intake or correlate it with stool outcomes between visits
• Physicians have no objective basis for dose adjustment other than patient report
• Underdosing leads to ongoing malabsorption and nutritional deficiency
• Overdosing is associated with fibrosing colonopathy risk in pediatric populations and unnecessary cost in adults

A structured log linking fat intake (grams per meal), enzyme dose (units administered), and bowel outcome (Bristol type, oiliness) creates the data substrate needed to identify effective dosing patterns for individual patients — data that does not currently exist in clinical practice at scale.

Post-TPIAT Management Gap

Total pancreatectomy with islet autotransplantation (TPIAT) eliminates the native pancreas entirely. Post-operative patients face simultaneous management of:

• Complete exocrine insufficiency (100% PERT dependence)
• Variable insulin secretion from autotransplanted islets (partial to complete insulin independence)
• Glucose instability that does not follow T1D or T2D patterns
• Ongoing pain management in a subset of patients with central sensitization

There is no disease-specific monitoring platform for this population. Post-TPIAT patients are often managed using tools designed for T1D (for glucose) and generic GI apps (for symptoms) — none of which integrate the relevant variables or produce clinically useful summaries.

The Underdiagnosis Problem in EPI

Studies estimate that EPI diagnosis is delayed by an average of 4–5 years from symptom onset. Contributing factors include:

• Symptom overlap with IBS, IBD, and functional GI disorders
• Low clinician awareness outside gastroenterology and pancreatic disease specialists
• Lack of structured symptom documentation that could trigger differential diagnosis

Longitudinal bowel tracking with structured steatorrhea flagging (Bristol type 7, oily/floating stool) creates a documentable symptom timeline that can support earlier fecal elastase testing and diagnosis referral.